Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.

Elliott, Perry; Gundapaneni, Balarama; Sultan, Marla B; Ines, Monica; Garcia-Pavia, Pablo

Elliott, Perry; Gundapaneni, Balarama; Sultan, Marla B; Ines, Monica; Garcia-Pavia, Pablo.

Affiliation

Elliott P; University College London, London, UK.
Gundapaneni B; Pfizer Inc, Groton, CT, USA.
Sultan MB; Pfizer Inc, New York, NY, USA.
Ines M; Pfizer Inc, Porto Salvo, Portugal.
Garcia-Pavia P; Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain.

Eur J Heart Fail ; 25(11): 2060-2064, 2023 11.

Article in En | MEDLINE | ID: mdl-37434378

Subject(s)

Amyloid Neuropathies, Familial; Cardiomyopathies; Heart Failure; Humans; Amyloid Neuropathies, Familial/complications; Amyloid Neuropathies, Familial/drug therapy; Prealbumin; Heart Failure/drug therapy; Heart Failure/complications; Cardiomyopathies/drug therapy; Cardiomyopathies/complications

Key words

ATTR-ACT; Amyloidosis; Prognosis; Survival rate; Trial

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amyloid Neuropathies, Familial / Heart Failure / Cardiomyopathies Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Eur J Heart Fail Journal subject: CARDIOLOGIA Year: 2023 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google